Tivic Health Systems, Inc. (NASDAQ:TIVC) Sees Large Decrease in Short Interest

Posted by James Quigley on Nov 16th, 2024

Tivic Health Systems, Inc. (NASDAQ:TIVC – Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 111,300 shares, a drop of 32.7% from the October 15th total of 165,300 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 5,120,000 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Tivic Health Systems

A hedge fund recently bought a new stake in Tivic Health Systems stock. Warberg Asset Management LLC bought a new position in Tivic Health Systems, Inc. (NASDAQ:TIVC – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 80,000 shares of the company’s stock, valued at approximately $31,000. Warberg Asset Management LLC owned 1.29% of Tivic Health Systems as of its most recent filing with the Securities & Exchange Commission. 4.25% of the stock is currently owned by hedge funds and other institutional investors.

Tivic Health Systems Stock Performance

Tivic Health Systems stock traded down $0.08 during trading hours on Friday, reaching $0.29. 2,159,292 shares of the company’s stock traded hands, compared to its average volume of 3,192,011. Tivic Health Systems has a fifty-two week low of $0.22 and a fifty-two week high of $3.21. The firm’s 50 day moving average is $0.28 and its 200-day moving average is $0.39.

Tivic Health Systems (NASDAQ:TIVC – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.32) EPS for the quarter. Tivic Health Systems had a negative return on equity of 172.08% and a negative net margin of 606.47%. The business had revenue of $0.14 million for the quarter.

About Tivic Health Systems

(Get Free Report)

Tivic Health Systems Inc operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S.